Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Interleukin-2”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Post-approval studies (Phase 4)Study completedNCT02360592
What this trial is testing

Combination Therapy With Interferon Plus Interleukin 2 and Hepatitis B Vaccine in Chronic Hepatitis B Patients

Who this might be right for
Hepatitis B, Chronic
Tongji Hospital 94
Early research (Phase 1)Study completedNCT03213964
What this trial is testing

Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int

Who this might be right for
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota 10
Large-scale testing (Phase 3)Study completedNCT00502034
What this trial is testing

Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma.

Who this might be right for
Carcinoma, Renal Cell
Gruppo Oncologico Italiano di Ricerca Clinica 310
Testing effectiveness (Phase 2)Study completedNCT01883323
What this trial is testing

Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma

Who this might be right for
Metastatic, Stage III or Stage IV, Melanoma
University Health Network, Toronto 12
Testing effectiveness (Phase 2)Ended earlyNCT00505635
What this trial is testing

Biochemotherapy With Temozolomide for Metastatic Melanoma

Who this might be right for
Melanoma
M.D. Anderson Cancer Center 5
Testing effectiveness (Phase 2)Study completedNCT01827735
What this trial is testing

Regulatory T Cells in Type 1 Diabetes Patients Treated With IL-2

Who this might be right for
Type 1 Diabetes
Cambridge University Hospitals NHS Foundation Trust 40
Testing effectiveness (Phase 2)Study completedNCT00002637
What this trial is testing

Biological Therapy in Treating Patients With Prostate Cancer

Who this might be right for
Prostate Cancer
Memorial Sloan Kettering Cancer Center 25
Not applicableStudy completedNCT00001131
What this trial is testing

Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 42
Not applicableStudy completedNCT00001353
What this trial is testing

Safety and Survival of Genetically Modified White Blood Cells in HIV-Infected Persons - A Study in Identical Twin Pairs

Who this might be right for
Acquired Immunodeficiency SyndromeHIV Infection
National Institute of Allergy and Infectious Diseases (NIAID) 24
Testing effectiveness (Phase 2)Study completedNCT03113773
What this trial is testing

Low Dose Interleukin-2 in Patients With Stable Ischaemic Heart Disease and Acute Coronary Syndromes

Who this might be right for
Ischemic Heart Disease
Cambridge University Hospitals NHS Foundation Trust 41
Large-scale testing (Phase 3)Study completedNCT00001812
What this trial is testing

A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2

Who this might be right for
Candidiasis, OralGastrointestinal DiseasesStomatitis
National Cancer Institute (NCI) 84
Testing effectiveness (Phase 2)Study completedNCT00006033
What this trial is testing

Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer

Who this might be right for
Head and Neck Cancer
H. Lee Moffitt Cancer Center and Research Institute
Testing effectiveness (Phase 2)Study completedNCT00136448
What this trial is testing

High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML)

Who this might be right for
Acute Myelogenous Leukemia
Dana-Farber Cancer Institute 30
Early research (Phase 1)Looking for participantsNCT06641648
What this trial is testing

A Phase I Single-arm Clinical Study of Donor NK Cells Infusion Combined With Low-dose Interleukin-2 in the Treatment of Acute Myeloid Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation.

Who this might be right for
Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia (AML) RelapseNK Cell
Peking University First Hospital 12
Early research (Phase 1)Study completedNCT00970996
What this trial is testing

Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma

Who this might be right for
Melanoma
M.D. Anderson Cancer Center 10
Early research (Phase 1)Study completedNCT00005576
What this trial is testing

Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma

Who this might be right for
Disseminated NeuroblastomaRecurrent NeuroblastomaRegional Neuroblastoma
National Cancer Institute (NCI) 6
Testing effectiveness (Phase 2)Ended earlyNCT00913913
What this trial is testing

Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients

Who this might be right for
Metastatic Renal Cell Carcinoma
Dartmouth-Hitchcock Medical Center 8
Early research (Phase 1)Active Not RecruitingNCT01955460
What this trial is testing

Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma

Who this might be right for
Metastatic MelanomaStage III Cutaneous Melanoma AJCC v7Stage IIIA Cutaneous Melanoma AJCC v7+3 more
M.D. Anderson Cancer Center 34
Testing effectiveness (Phase 2)Study completedNCT01988506
What this trial is testing

Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases

Who this might be right for
Rheumatoid ArthritisAnkylosing SpondylitisSystemic Lupus Erythematosus+11 more
Assistance Publique - Hôpitaux de Paris 81
Not applicableLooking for participantsNCT07610538
What this trial is testing

Low-dose Interleukin-2 After Myocardial Infarction to Investigate Effects on Tissue-resident Regulatory T Cells

Who this might be right for
Coronary Artery DiseaseMyocardial Infarction (MI)CABG
Cambridge University Hospitals NHS Foundation Trust 24
Next Page